Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $115.00.

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price target of $105.00. Mohit Bansal has given his Buy ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. Galapagos NV plans to split into two entities ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

Gilead Sciences has taken a major step towards ... significant milestones in two pivotal Phase 3 trials PURPOSE 1 and PURPOSE 2. Data from both studies showcased the superiority of twice-yearly ...

Gilead Sciences has shored up its antibody-drug ... It also hopes to start a phase 1/2 trial of its next candidate – 5T4-targeting TUB-030 – in solid tumours before the end of the year.

For 2025, Browning has another “Radical In The Family” with its new X-Bolt 2 All Purpose bolt-action rifle. Many would put the All Purpose in the “ranch rifle” category, but to be frank ...

In recent trading, Gilead Sciences Inc (GILD) stock price has shown some volatility, fluctuating 0.58% over the last five trades and 2.01% over the past 30 trades. This represents a notable shift from ...